Movement Disorders Emergencies Part 1
, Robottom, B.J., et al, 2011
Statin Use and the Risk of Parkinson Disease
Neurol 70:1418-1422, Wahner,A.D.,et al, 2008
Use of Antihypertensives and the Risk of Parkinson Disease
Neurol 70:1438-1444, Becker,C.,et al, 2008
Dystonia
NEJM 355:818-829, Tarsy,D. &Simon,D.K., 2006
The Serotonin Syndrome
NEMJ 352:1112-20, Boyer, E.W. & Shannon, M., 2005
Treatment of Drug-Induced Psychosis with Quetiapine and Clozapine in Parkinson's Disease
Neurol 55:1753-1754, Dewey,R.B.Jr. & O'Suilleabhain,P.E., 2000
Low-Dose Clozapine for the Treatment of Drug-Induced Psychosis in Parkinson's Disease
NEJM 340:757-763,801, The Parkinson Study Group, 1999
Neuroleptic Drug Exposure and Treatment of Parkinsonism in the Elderly:A Case-Control Study
Am J Med 99:48-54, Avorn,J.,et al, 1995
Olanzapine in the Treatment of Dopaminomimetic Psychosis in Patients with Parkinson's Disease
Neurol 47:1085-1087, Wolters,W.Ch.,et al, 1992
Neuroleptic-Induced Parkinson's Syndrome:Clinical Features and Results of Treatment with Levodopa
JNNP 51:850-854, Hardie,R.J.&Lees,A.J., 1988
Vitamin B12 Deficiency:NICE Guideline Summary
BMJ 385:q1019, q1262, Sands,T.,et al, 2024
Posterior Reversible Encephalopathy Syndrome
NEJM 388:2171-2178, Geocadin,R.G., 2023
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Involuntary Groaning Induced by Levodopa Therapy in a Patient With Progressive Supranuclear Palsy
JAMA Neurol 77:1569, Park, J.E., 2020
Clinicopathologic Conference, Statin-Associated Autoimmune Myopathy
NEJM 381:275-283, Case 22-2019, 2019
Cerebellar Hippocampal and Basal Nuclei Transient Edema with Restricted Diffusion (CHANTER) Syndrome
Neurocrit Care 31:228-296, Jasne, A.S.,et al, 2019
Drug Reaction with Eosinophilia and Systemic Symptoms after Daclizamub Therapy
Neurol 91:e359-e363, Rauer,S.,et al, 2018
Cytotoxic Lesions of the Corpus Callosum That Show Restricted Diffusion: Mechanisms, Causes, and Manifestations
RadioGraphics 37:562-576, Starkey, J.,et al, 2017
A Case of Statin-Associated Autoimmune Myopathy
Clin Med Insights: Case Reports 10:1-4, Sweidan, A.J.,et al, 2017
Antibiotic-Associated Encephalopathy
Neurol 86:963-971, Bhattacharyya, S.,et al, 2016
Dystonia in Children and Adolescents: A Systematic Review and a New Diagnostic Algorithm
JNNP 86:774-781, Van Egmond, M.E.,et al, 2015
Statins and Intracerebral Hemorrhage
Arch Neurol 69:39-45,13, Hackam,D.G,et al, 2012
Clinicopathologic Conference,Necrotizing Noninflammatory Myopathy Consistent with Exposure to Statins
NEJM 36:944-954, Case 7-2012, 2012
Dropped Head Syndrome: Report of Three Cases During Treatment with a Mek Inhibitor
Neurol 79:1929-1932, Chen, X.,et al, 2012
Spectrum of Neurologic Complications in Chronic Lymphocytic Leukemia
Clin Lymphoma Myeloma Leuk 12:164-179, Lopes da Silva, R., 2012
Reversible Cerebral Vasoconstruction Syndromes
Arch Neurol 68:1005-1012,976, Singhal, A.B.,et al, 2011
Toxic and Drug-Induced Myopathies
JNNP 80:832-838, Dalakas,M.C., 2009
Narrative Review: Reversible Cerebral Vasoconstriction Syndromes
Ann Intern Med 146:34-44, Calabrese,L.H.,et al, 2007
The Clinical and Radiological Spectrum of Reversible Cerebral Vasoconstriction Syndrome. A Prospective Series of 67 Patients
Brain 130:3091-3101, Ducros, A.,et al, 2007
What is the Risk of Developing Parkinsonism Following Neuroleptic Use?
Neurol 66:941-943, Noyes,K.,et al, 2006
Statin-Associated Myasthenia Gravis
Medicine 85:82-85, Purvin,V.,et al, 2006
Pathological Gambling Caused by Drugs Used to Treat Parkinson Disease
Arch Neurol 62:1377-1381, Dodd,M.L.,et al, 2005
Reversible Anorgasmia With Topiramate Therapy for Migraine
Neurol 65:1333-1334, Newman,L.C.,et al, 2005
Underappreciated Statin-Induced Myopathic Weakness Causes Disability
Neurorehabil Neural Repair 19:259-263, Dobkin,B.H., 2005
Reversible Parkinsonism with Normal B-CIT-SPECT in Patients Exposed to Sodium Valproate
Neurol 62:1435-1437, Easterford,K.,et al, 2004
Bilateral Anterior Toxic Optic Neuropathy and the Use of Infliximab
BMJ 326:579, ten Tusscher,M.P.M.,et al, 2003
Neurological Aspects of Taste Disorders
Arch Neurol 60: 667-671, Heckmann,J.G.,et al, 2003
Management of Drug and Alcohol Withdrawal
NEJM 348:1786-1795, Kosten,T.R. &O'Connor,P.G., 2003
Statin-Associated Myopathy
JAMA 289:1681-1690, Thompson,P.D.,et al, 2003
Doxycycline Induced Intracranial Hypertension
BMJ 326:641-642,613, Lochhead,J. &Elston,J.S., 2003
The Risk-Benefit Profile of Commonly Used Herbal Therapies: Ginkgo, St. John's Wort, Genseng, Echinacea, Saw Palmetto, and Kava
Ann Int Med 136:42-53, Ernst,E., 2002
Features of Medication Overuse Headache Following Overuse of Different Acute Headache Drugs
Neurol 59:1011-1014,972, Limmroth,V.,et al, 2002
Burning Mouth Syndrome
Am Fam Physician 65:615-620, Gruska,M.,et al, 2002
Serotonin Sydrome
Medicine 79:201-209, Mason,P.J. et al, 2000
Parkinsonism after Taking Ecstasy
NEJM 340:1443, Mintzer,S.,et al, 1999
Effectiveness of Anticholinergics and Neuroleptic Dose Reduction on Neuroleptic-Induced Pleurothotonus (the Pisa Syndrome)
J Clin Psychopharmacol 19:277-280, Suzuki,T.,et al, 1999
Secondary Hyperkalaemic Paralysis
JNNP 64:249-252, Evers,S.,et al, 1998
An Algorithm (Decision Tree) for the Management of Parkinson's Disease:Trtm Guidelines
Neurol 50:S1-S57, Olanow,C.W.&Koller,W.C., 1998
Acute, Drug-Induced, Life-Threatening Neurological Syndromes
The Neurologist 4:196-210, Richard,I.H., 1998